Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-α and retinoic acid

Anticancer Research

Volumn 18, Issue 3 B, 1998, Pages 1883-1890

  Elsasser Beile U ^a,b   Kolble N ^a   Grussenmeyer, T ^a   Wetterauer, U ^a   Schultze Seemann, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Experimental Research Group   (Germany)

Author keywords

Cytokine therapy; Immunological monitoring; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; RETINOIC ACID; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD CELL; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; EVALUATION STUDIES; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TIME FACTORS; TRETINOIN;

EID: 0031879763     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Stahl M, Wilke H-J, Seeber S and Schmoll H-J: Cytokines and cytotoxic agents in renal cell carcinoma: a review. Sem Oncol 19: 70-79,1992.
2. Kopp WC, Holmlund JT and Urba WJ: Immunological monitoring and clinical trials of biological response modifiers. In. Cancer Chemotherapy and Biological Response Modifiers (Annual 15) (Pinedo HM, Longo DL, Chabner BA, eds). Elsevier Science, 1994, pp 226-286.
3. Kopp WC and Holmlund JT: Cytokines and immunological monitoring. In: Cancer Chemotherapy and Biological Response Modifiers (Annual 16) (Pinedo HM, Longo DL, Chabner BA, eds). Elsevier Science, 1996, pp 189-238.
4. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V and Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950-1957,1995.
5. Sondel PM, Kohler PC, Hank JA, Moore KH. Rosenthal NS, Sosman JA, Bechhofer R and Storer B: Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 48: 2561-2567, 1988.
6. Blay J-Y, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlein P, Franks CR and Philip T: Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 50: 2371-2374,1990.
7. Gratama JW, Schmitz PI, Goey SH, Lamers CH, Stoter G and Bolhuis RL: Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes). Int J Cancer 65: 152-160, 1996.
8. Fossa SD, Aamdal S, Naume B and Gallati H: Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-α combination therapy. Acta Oncol 34: 599-603, 1995.
9. Elsasser-Beile U, von Kleist S, Fischer R and Schulte Monting J: Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls. J Clin Lab Anal 6: 311-314, 1992.
10. Elsasser-Beile U, von Kleist S, Martin M, Gallati H and Schulte Monting J: Impaired cytokine production in whole blood cell cultures of patients with gynecological carcinomas in different clinical stages. Br J Cancer 68: 32-36,1993.
11. Elsasser-Beile U, von Kleist S, Stahle W, Schurhammer-Fuhrmann C, Schulte Monting J and Gallati H: Cytokine levels in whole blood cell cultures as parameters of the cellular immunological activity in patients with malignant melanoma and basal cell carcinoma. Cancer 71: 231-236, 1993.
12. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D and Kushtai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer. Cancer Res 51: 5602-5607, 1991.
13. Elsasser-Beile U, Gallati H, Weber W, Wild ED, Schulte Monting J and von Kleist S: Increased plasma concentrations for type I and II tumor necrosis factor receptors and 1L-2 receptors in cancer patients. Tumor Biol 15: 17-24,1994.
14. Elsasser-Beile U, von Kleist S and Gallati H: Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Meth 139: 191-195, 1991.
15. Einhorn S, Ling P, Einhorn N and Strander H: The capacity of blood lymphoid cells to produce α- and γ-interferon is decreased during alpha-interferon therapy. J Clin Lab Immunol 23: 35-38, 1987.
16. Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C and Neraas KA: Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47: 4202-4207, 1987.
17. Pawelec G, Schwulera U, Lenz H, Owsianowski M, Buhring HJ, Schlag H, Schneider E, Schadt K and Ehninger G: Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2. Mol Biother 2: 44-49, 1990.
18. Hayat K, Rodgers S, Bruce L, Rees R, Chapman K, Reeder S, Dorreen MS, Sheridan E, Sreenivasan T and Hancock BW: Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2. Eur J Cancer 27: 1009-1014,1991.
19. McIntyre CA, Chapman K, Reeder S, Dorreen MS, Bruce L, Rodgers S, Hayat K, Sreenivasan T, Sheridan E, Hancock BW and Rees R: Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 28: 58-63,1992.
20. Miles DW, Aderka D, Engelmann H, Wallach D and Balkwill FR: Induction of soluble tumor necrosis factor receptors during treatment with interleukin-2. Brit J Cancer 66: 1195-1199, 1992.
21. Farace F, Pallardy M, Angevin E, Hercend T, Escudier B and Triebel F: Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: immunological monitoring. Int J Cancer 57: 814-821, 1994.
22. Landmann R, Keilholz U, Scheibenbogen C, Brockhaus M, Gallati H, Denz H, Bargetzi M and Ludwig C: Relationship between sloluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. Cancer Immunol Immunother 38: 113-118, 1994.
23. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C. Ish C, Buchanan L, Perillo D and et al: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 9: 2110-2119, 1991.
24. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ and et al: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91: 123-132, 1993.
25. Lindemann A, Brossart P, Hoffken K, Flasshove M, Voliotis D, Diehl V, Hecker G, Wagner H and Mertelsmann R: Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother 37: 307-315, 1993.
26. Lindemann A, Brossart P, Höffken K, Flasshove M, Voliotis D, Diehl V, Kulmburg P, Wagner H and Mertelsmann R: Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunother 15: 225-230, 1994.
27. Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Dellemijn TA, Rodenhuis S and Melief CJ: A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. Br J Cancer 68: 559-567, 1993.
28. Atzpodien J, Kirchner H, Korfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I and et al: Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-α-2. Tumor Biol 14: 354-359, 1993.
29. Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R and Monson JR: Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Eur J Surg Oncol 19: 265-272,1993.
30. Tartour F, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Poullart P and Fridman WH: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911-913, 1994.
31. Schneekloth C, Korfer A, Hadam M, Lopez Hanninen E, Menzel T, Schomburg A. Dallmann I, Kirchner H, Poliwoda H and Atzpodien J: Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 89: 13-21,1993.
32. 2b. Tumor Biol 16: 365-373, 1995.